PD-L1 Detection on Circulating Melanoma Cells.

Autor: Po JW; Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia. joseph.po@health.nsw.gov.au.; Centre for Oncology Education and Research Translation (CONCERT), Liverpool, NSW, Australia. joseph.po@health.nsw.gov.au.; Western Sydney University, School of Medicine, Campbelltown, NSW, Australia. joseph.po@health.nsw.gov.au., Ma Y; Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.; Centre for Oncology Education and Research Translation (CONCERT), Liverpool, NSW, Australia.; University of New South Wales, School of Medicine, Kensington, NSW, Australia., Balakrishnar B; Liverpool Hospital, Liverpool, NSW, Australia., Brungs D; Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.; Centre for Oncology Education and Research Translation (CONCERT), Liverpool, NSW, Australia.; University of Wollongong, School of Medicine, Wollongong, NSW, Australia.; Illawarra Cancer Centre, Wollongong Hospital, Wollongong, NSW, Australia., Azimi F; Liverpool Hospital, Liverpool, NSW, Australia., Cooper A; Centre for Oncology Education and Research Translation (CONCERT), Liverpool, NSW, Australia.; Western Sydney University, School of Medicine, Campbelltown, NSW, Australia.; Liverpool Hospital, Liverpool, NSW, Australia., Saricilar E; Western Sydney University, School of Medicine, Campbelltown, NSW, Australia.; University of New South Wales, School of Medicine, Kensington, NSW, Australia.; Liverpool Hospital, Liverpool, NSW, Australia.; University of Sydney, Camperdown, NSW, Australia., Murthy V; Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.; Centre for Oncology Education and Research Translation (CONCERT), Liverpool, NSW, Australia.; Western Sydney University, School of Medicine, Campbelltown, NSW, Australia.; Liverpool Hospital, Liverpool, NSW, Australia., de Souza P; Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.; Western Sydney University, School of Medicine, Campbelltown, NSW, Australia.; University of New South Wales, School of Medicine, Kensington, NSW, Australia.; Liverpool Hospital, Liverpool, NSW, Australia.; University of Wollongong, School of Medicine, Wollongong, NSW, Australia., Becker TM; Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.; Centre for Oncology Education and Research Translation (CONCERT), Liverpool, NSW, Australia.; Western Sydney University, School of Medicine, Campbelltown, NSW, Australia.; University of New South Wales, School of Medicine, Kensington, NSW, Australia.
Jazyk: angličtina
Zdroj: Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2021; Vol. 2265, pp. 223-233.
DOI: 10.1007/978-1-0716-1205-7_17
Abstrakt: The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the treatment of a range of melanoma, showing a profound improvement in the overall survival outcomes. However, immune checkpoint inhibitors (ICIs) are associated with considerable toxicities and appear to only be efficacious in a subset of melanoma patients. Therefore, there is an urgent need to identify biomarkers that can determine if patients will or will not respond to ICI therapy. Here, we describe an optimized method for analyzing PD-L1 expression on circulating melanoma cells following immunomagnetic enrichment from patient blood samples.
Databáze: MEDLINE